In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae

Journal of Infection and Chemotherapy

Volumn 9, Issue 1, 2003, Pages 12-15

  Dhople, Arvind M ^a   Namba, Kenji ^b  

^a Florida Institute of Technology ^*  (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

3H thymidine; ATP; Fluoroquinolones; M. leprae; Rifamycins; Sitafloxacin

Indexed keywords

ADENOSINE TRIPHOSPHATE; CIPROFLOXACIN; CLOFAZIMINE; DAPSONE; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMPICIN DERIVATIVE; SITAFLOXACIN; SULFONE; THYMIDINE; TRITIUM;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CULTURE MEDIUM; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SCREENING; IN VITRO STUDY; LEPROSY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM LEPRAE;

EID: 0037366290     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-002-0212-8     Document Type: Article

References (29)

1. Faget GH, Pogge RC, Johansen FA, Dinan JH, Prejean BM, Eccles CG. The promin treatment of leprosy: a progress report. Public Health Rep 1943;58:1729-41.
2. Cochrane RG, Ramanujam K, Paul H, Russel D. Two and a half years experimental work on the sulfone groups of drugs. Lepr Rev 1949;20:4-64.
3. Brown SG, Hogerzeil LM. 'B663' in the treatment of leprosy: preliminary report of a pilot trial. Lepr Rev 1962;33:6-10.
4. Rees RJW, Pearson JMH, Waters MFR. Experimental and clinical studies on rifampicin in treatment of leprosy. BMJ 1970;1:89-92.
5. Petit JHS, Rees RJW. Sulphone resistance in leprosy: an experimental and clinical study. Lancet 1964;11:673-4.
6. Jacobson RR, Hastings RC. Rifampin-resistant leprosy. Lancet 1976;II:1304-5.
7. Worndorff-can Diepen T. Clofazimine-resistant leprosy - a case report. Int J Lepr 1982;50:7139-42.
8. World Health Organization. Chemotherapy of leprosy for control programs. Geneva, Switzerland: WHO Technical Reptort Service; 1982. p. 675.
9. World Health Organization. Report of the first meeting of the WHO Working Group in Leprosy Control. Int J Lepr 1992;60: 114-9.
10. World Health Organization. Remaining challenges towards the elimination of leprosy. Indian J Lepr 2000;72:33-45.
11. Ji B. Drug resistance in leprosy. Lepr Rev 1985;56:265-78.
12. Chen XS, Li WZ, Jiang C, Ye GY. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy. Int J Lepr 1999;67:379-87.
13. Shaw IN, Ibenezer G, Rao GS, Natarajan MM, Balasundaram MM. Relapses as histoid leprosy after receiving multidrug therapy: a report of three cases. Int J Lepr 2000;68:272-6.
14. Dhople AM, Ibanez MA, Gardner GD. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae. Arzneim-Forsch/Drug Res 1993;43:384-6.
15. Dhople AM, Ibanez MA. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Arzneim-Forsch/Drug Res 1994;44:563-5.
16. Dhople AM, Ibanez MA. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae. Antimicrob Agents Chemother 1995;39:2116-9.
17. Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992;36:1491-8.
18. Sato H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother 1994;38:2877-82.
19. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-5869a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999;43:3001-4.
20. World Health Organization. Purification of M. leprae. Annex 4 of report of the fifth meeting of the SWG on the immunology of leprosy, Geneva, 24-26 June 1980. WHO Document No. TDR/ IMMLEP-SWG (5) 80.3.
21. Hanks JH, Chatterjee BR, Lechat MF. A guide to the counting of mycobacteria in clinical and experimental materials. Int J Lepr 1964;32:156-67.
22. Dhople AM, Green KJ, Osborne LJ. Limited in vitro multiplication of Mycobacterium leprae. Ann Inst Pasteur Microbiol 1988;139:213-23.
23. Dhople AM, Ortega I. An in vitro culture method for screening new drugs against Mycobacterium leprae. Indian J Lepr 1990;62:66-75.
24. 3H-thymidine to determine drug sensitivity of Mycobacterium leprae. IRCS Med Sci 1986;14:807-8.
25. Dhople AM, Green KJ. Limited in vitro multiplication of Mycobacterium leprae: application to screening potential antileprosy compounds. Lepr Rev 1986;57:149-62.
26. Khanolkar SR, Ambrose EJ, Chulawala RG, Bapat CV. Autoradiographic and metabolic studies of Mycobacterium leprae. Lepr Rev 1978;49:187-98.
27. Dhople AM, Ibanez MA. In vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae. J Antimicrob Chemother 1995;35:463-71.
28. Dhople AM, Hanks JH. In vitro growth of Mycobacterium lepraemurium, an obligate intracellular microbe. Science 1977;197:379-81.
29. Beckers B, Lang HRM, Schimke D, Lammers A. Evaluation of a bioluminescence assay for rapid antimicrobial susceptibility testing of mycobacteria. Eur J Clin Microbiol 1985;4:556-61.